NasdaqGM - Nasdaq Real Time Price • USD
Supernus Pharmaceuticals, Inc. (SUPN)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:13 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 0.38 | 0.37 | 1.64 | 1.95 |
| Low Estimate | 0.29 | 0.35 | 1.53 | 1.04 |
| High Estimate | 0.48 | 0.4 | 1.8 | 2.55 |
| Year Ago EPS | 0.7 | 0.49 | 2.01 | 1.64 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 145.83M | 148.79M | 601.46M | 614.71M |
| Low Estimate | 143.6M | 145M | 594.1M | 582.02M |
| High Estimate | 151.9M | 153.07M | 609.84M | 661.7M |
| Year Ago Sales | 139.02M | 143.66M | 607.52M | 601.46M |
| Sales Growth (year/est) | 4.90% | 3.60% | -1.00% | 2.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.17 | 0.06 | 0.08 | 0.55 |
| EPS Actual | 0.7 | 0.49 | 0.24 | 0.89 |
| Difference | 0.53 | 0.43 | 0.16 | 0.34 |
| Surprise % | 311.80% | 716.70% | 200.00% | 61.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.38 | 0.37 | 1.64 | 1.95 |
| 7 Days Ago | 0.38 | 0.37 | 1.64 | 1.95 |
| 30 Days Ago | 0.38 | 0.37 | 1.64 | 1.95 |
| 60 Days Ago | 0.38 | 0.43 | 1.8 | 2.15 |
| 90 Days Ago | 0.4 | 0.45 | 1.9 | 2.19 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SUPN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -45.70% | -- | -- | 1.60% |
| Next Qtr. | -24.50% | -- | -- | 10.50% |
| Current Year | -18.40% | -- | -- | 5.20% |
| Next Year | 18.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 1.69% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -17.31% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight to Overweight | 2/28/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/9/2023 |
| Maintains | Piper Sandler: Overweight to Overweight | 10/25/2023 |
| Maintains | Piper Sandler: Overweight to Overweight | 5/10/2023 |
| Maintains | Piper Sandler: Overweight | 1/23/2023 |
| Maintains | Piper Sandler: Overweight | 8/31/2022 |
Related Tickers
IRWD Ironwood Pharmaceuticals, Inc.
7.92
+4.21%
DCPH Deciphera Pharmaceuticals, Inc.
14.67
+3.09%
COLL Collegium Pharmaceutical, Inc.
34.84
+0.20%
ALKS Alkermes plc
23.85
+0.38%
PCRX Pacira BioSciences, Inc.
26.25
+0.57%
PETQ PetIQ, Inc.
16.28
+1.56%
NBIX Neurocrine Biosciences, Inc.
132.00
-0.41%
ANIP ANI Pharmaceuticals, Inc.
65.48
+1.39%
EOLS Evolus, Inc.
11.53
-0.26%
OPTN OptiNose, Inc.
0.8942
-3.61%